Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mapatumumab with cisplatin and radiotherapy for advanced cervical cancer
NL-OMON35431Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mapatumumab in Cervical Cancer (CC), sponsored by University Medical Center Groningen. Primary endpoints: Safety and tolerability of mapatumumab in combination with cisplatin and radiotherapy and Efficacy of mapatumumab in combination with cisplatin and radiotherapy. Started Nov 2010; status: active, not recruiting.
02
Drugs
mapatumumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON35431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35431.